These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
161 related items for PubMed ID: 9671018
1. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H. Am J Cardiol; 1998 Jul 01; 82(1):113-7. PubMed ID: 9671018 [Abstract] [Full Text] [Related]
6. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Circulation; 2005 Nov 15; 112(20):3168-73. PubMed ID: 16286607 [Abstract] [Full Text] [Related]
8. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. Elmberger PG, Kalén A, Lund E, Reihnér E, Eriksson M, Berglund L, Angelin B, Dallner G. J Lipid Res; 1991 Jun 15; 32(6):935-40. PubMed ID: 1940625 [Abstract] [Full Text] [Related]
9. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. Betteridge DJ, Bhatnager D, Bing RF, Durrington PN, Evans GR, Flax H, Jay RH, Lewis-Barned N, Mann J, Matthews DR. BMJ; 1992 May 23; 304(6838):1335-8. PubMed ID: 1611329 [Abstract] [Full Text] [Related]
12. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson SO, Berglund L, Lindén T, Sjöberg A, Bondjers G. J Intern Med; 1990 Sep 23; 228(3):241-7. PubMed ID: 2119417 [Abstract] [Full Text] [Related]
13. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Illingworth DR, Bacon S. Arteriosclerosis; 1989 Sep 23; 9(1 Suppl):I121-34. PubMed ID: 2492189 [Abstract] [Full Text] [Related]
14. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Leitersdorf E, Muratti EN, Eliav O, Peters TK. Am J Cardiol; 1995 Jul 13; 76(2):84A-88A. PubMed ID: 7604807 [Abstract] [Full Text] [Related]
15. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. O'Neill FH, Patel DD, Knight BL, Neuwirth CK, Bourbon M, Soutar AK, Taylor GW, Thompson GR, Naoumova RP. Arterioscler Thromb Vasc Biol; 2001 May 13; 21(5):832-7. PubMed ID: 11348882 [Abstract] [Full Text] [Related]
16. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. Mabuchi H, Sakai T, Sakai Y, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J, Takeda R. N Engl J Med; 1983 Mar 17; 308(11):609-13. PubMed ID: 6828091 [Abstract] [Full Text] [Related]
17. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II. Arch Intern Med; 1993 Jun 14; 153(11):1321-9. PubMed ID: 8507122 [Abstract] [Full Text] [Related]